Editorial: The use of real world data for regulatory purposes in the rare diseases setting by Viviana Giannuzzi, Violeta Stoyanova-Beninska, Virginie Hivert

Get full text

Real-world evidence (RWE): A challenge for regulatory agencies discussion of the RWE conference with the network of the european medicine agencies, patients, and experts by Patrick Maison, Patrick Maison, Mahmoud Zureik, Virginie Hivert, Jesper Kjaer, Roman Hossein Khonsari, Gianluca Trifirõ, Christelle Ratignier-Carbonneil

Get full text

How to START? Four pillars to optimally begin your orphan drug development by Anneliene Hechtelt Jonker, Liliana Batista, Michela Gabaldo, Virginie Hivert, Diego Ardigo, on behalf of the IRDiRC ODDG TF and IRDiRC TSC

Get full text

Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases by Marta del Álamo, Christoph Bührer, Dirk Fisher, Matthias Griese, Paul Lingor, Giovanni Palladini, Nicolas Sireau, Virginie Hivert, Luca Sangiorgi, Florence Guillot, Juliane Halftermeyer, Lenka Soucková, Kristýna Nosková, Regina Demlová

Get full text